Don't lose heart - therapeutic value of apoptosis prevention in the treatment of cardiovascular disease
View/ Open
Full Text
Date
2005-07-01Author
Reeve, Janice L. V.
Duffy, Angela M.
O'Brien, Timothy
Samali, Afshin
Metadata
Show full item recordUsage
This item's downloads: 0 (view details)
Cited 92 times in Scopus (view citations)
Recommended Citation
Reeve, Janice L. V. Duffy, Angela M.; O'Brien, Timothy; Samali, Afshin (2005). Don't lose heart - therapeutic value of apoptosis prevention in the treatment of cardiovascular disease. Journal of Cellular and Molecular Medicine 9 (3), 609-622
Abstract
Cardiovascular disease is a leading cause of death worldwide. Loss of function or death of cardiomyocytes is a major contributing factor to these diseases. Cell death in conditions such as heart failure and myocardial infarction is associated with apoptosis. Apoptotic pathways have been well studied in non-myocytes and it is thought that similar pathways exist in cardiomyocytes. These pathways include death initiated by ligation of membrane-bound death receptors, release of pro-apoptotic factors from mitochondria or stress at the endoplasmic reticulum. The key regulators of apoptosis include inhibitors of caspases (IAPs), the Bcl-2 family of proteins, growth factors, stress proteins, calcium and oxidants. The highly organized and predictive nature of apoptotic signaling means it is amenable to manipulation. A thorough understanding of the apoptotic process would facilitate intervention at the most suitable points, alleviating myocardium decline and dysfunction. This review summarizes the mechanisms underlying apoptosis and the mediators/regulators involved in these signaling pathways. We also discuss how the potential therapeutic value of these molecules could be harnessed.
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland
Related items
Showing items related by title, author, creator and subject.
-
The trail-receptor-1: trail-receptor-3 and -4 ratio is a predictor for trail sensitivity of cancer cells
Zwacka, (Spandidos Publications, 2009-04-06)The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in many cancer cells. However, a significant proportion of tumours are TRAIL-resistant erecting a major hurdle for a ... -
The janus face of death receptor signaling during tumor immunoediting
O’ Reilly, Eimear; Tirincsi, Andrea; Logue, Susan E.; Szegezdi, Eva (Frontiers Media SA, 2016-10-31)Cancer immune surveillance is essential for the inhibition of carcinogenesis. Malignantly transformed cells can be recognized by both the innate and adaptive immune systems through different mechanisms. Immune effector ... -
Targeting aml through dr4 with a novel variant of rhtrail
Szegezdi, Eva; Reis, Carlos R.; Sloot, Almer M. van der; Natoni, Alessandro; O’Reilly, Aoife; Reeve, Janice; Cool, Robbert H.; O’Dwyer, Michael; Knapper, Steven; Serrano, Luis; Quax, Wim J.; Samali, Afshin (Wiley-Blackwell, 2011-09-26)Despite progress in the treatment of acute myelogenous leukaemia (AML) the outcome often remains poor. Tumour necrosis factor related apoptosis-inducing ligand (TRAIL) is a promising therapeutic agent in many different ...